Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.72% | 174.07 | 0.0% | $1639.17m | |
| NVAX | Novavax, Inc. | -6.21% | 92.33 | 78.2% | $633.32m | |
| AMGN | Amgen, Inc. | -1.08% | 231.30 | 1.4% | $520.34m | |
| BIIB | Biogen, Inc. | -1.28% | 230.81 | 1.8% | $499.50m | |
| GILD | Gilead Sciences, Inc. | -1.93% | 69.07 | 1.0% | $465.79m | |
| BNTX | BioNTech SE | -4.47% | 161.66 | 0.0% | $438.57m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.13% | 618.11 | 2.7% | $392.67m | |
| ILMN | Illumina, Inc. | 0.32% | 384.36 | 3.3% | $386.08m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.10% | 230.84 | 1.9% | $334.35m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.00% | 2.88 | 0.7% | $201.32m | |
| EXAS | EXACT Sciences Corp. | -1.67% | 76.13 | 17.9% | $160.64m | |
| ARNA | Arena Pharmaceuticals, Inc. | -0.51% | 91.51 | 13.7% | $138.71m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -0.41% | 138.62 | 8.2% | $131.51m | |
| INCY | Incyte Corp. | -0.31% | 74.78 | 2.4% | $129.60m | |
| BBIO | BridgeBio Pharma, Inc. | -0.51% | 11.70 | 0.0% | $104.26m |
Company Profile
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.